U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. SIA "Piejura" - 557305 - 11/29/2018
  1. Warning Letters

CLOSEOUT LETTER

SIA "Piejura" MARCS-CMS 557305 —


Recipient:
Recipient Name
Mihails Silovs
Recipient Title
Manager
SIA "Piejura"
SIA "Piejura"

Nicas pagasts
Nicas novads
Avoti Liepajas Aprinkis 3473,
Latvia

Issuing Office:

United States


Dear Mr. Silovs:

The Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our Warning Letter 557305 issued on July 3, 2018. Based on our evaluation, it appears you have addressed the violations contained in the Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,
/S/
Robyn Jones,
Team Leader
Division of Enforcement
Office of Compliance
Center for Food Safety and Applied Nutrition

Back to Top